Genmab enters into collaboration with Traverse Biotech
This is a license agreement under which Traverse will develop and commercialize an antibody created based via Genmab technology.
by marketwire
Danish Genmab has entered into a cancer collaboration with Traverse Biotech. The US biotech company announces this in a press release.
The agreement is a license agreement under which Traverse will develop and commercialize a bispecific antibody based on Genmab’s Duobody technology.
The antibody is intended for the treatment of cancer.
Financial details of the collaboration are not disclosed in the announcement.
(Translated by DeepL with additional editing by Christian Radich Hoffman)
